CN1349611A - 诊断和监测恶性乳腺癌的方法 - Google Patents

诊断和监测恶性乳腺癌的方法 Download PDF

Info

Publication number
CN1349611A
CN1349611A CN00806967A CN00806967A CN1349611A CN 1349611 A CN1349611 A CN 1349611A CN 00806967 A CN00806967 A CN 00806967A CN 00806967 A CN00806967 A CN 00806967A CN 1349611 A CN1349611 A CN 1349611A
Authority
CN
China
Prior art keywords
biomarker
saliva
group
erbb
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00806967A
Other languages
English (en)
Chinese (zh)
Inventor
查尔斯·F·斯特雷克福斯
勒诺·G·比格勒
詹姆斯·T·西格彭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Mississippi Medical Center
Original Assignee
University of Mississippi Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Mississippi Medical Center filed Critical University of Mississippi Medical Center
Publication of CN1349611A publication Critical patent/CN1349611A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN00806967A 1999-03-01 2000-03-01 诊断和监测恶性乳腺癌的方法 Pending CN1349611A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/259,993 1999-03-01
US09/259,993 US6294349B1 (en) 1999-03-01 1999-03-01 Method of diagnosing and monitoring malignant breast carcinomas

Publications (1)

Publication Number Publication Date
CN1349611A true CN1349611A (zh) 2002-05-15

Family

ID=22987369

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00806967A Pending CN1349611A (zh) 1999-03-01 2000-03-01 诊断和监测恶性乳腺癌的方法

Country Status (11)

Country Link
US (3) US6294349B1 (fr)
EP (1) EP1161680A4 (fr)
JP (1) JP2002538462A (fr)
CN (1) CN1349611A (fr)
AU (1) AU3613400A (fr)
BR (1) BR0008709A (fr)
CA (1) CA2363566A1 (fr)
HK (1) HK1044816A1 (fr)
MX (1) MXPA01008794A (fr)
NO (1) NO20014223L (fr)
WO (1) WO2000052463A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100343280C (zh) * 2004-02-04 2007-10-17 香港中文大学 癌症病程及治疗反应的标志物cudr
CN101234026B (zh) * 2008-03-07 2010-04-14 李立 一种乳腺病变定量化影像评价系统
CN110297082A (zh) * 2019-06-12 2019-10-01 杭州启创生物技术有限公司 唾液尿酸等标志物特异性检测和诊断痛风的方法
CN111247432A (zh) * 2017-10-16 2020-06-05 亨利技术有限公司 使用唾液的乳腺癌检测试剂盒及乳腺癌检测方法以及使用唾液的可孕期检测试剂盒及可孕期检测方法

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294349B1 (en) * 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
CA2485970A1 (fr) * 2002-05-17 2004-04-08 Eastern Virginia Medical School Procedes de diagnostic de maladies mediees par htlv-1
US20040033613A1 (en) * 2002-05-30 2004-02-19 Zwick Michael G. Saliva-based protein profiling
JP2007506068A (ja) * 2003-08-05 2007-03-15 ユーロ−セルティーク エス．エイ． 化学療法耐性モニタリングのためのＥｒｂＢ受容体方法及びキット
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20050106642A1 (en) * 2003-11-19 2005-05-19 Lipps Binie V. Saliva test for early diagnosis of cancers
EP1730304B1 (fr) * 2004-02-20 2013-01-02 The Regents of the University of California Méthodes de profilage de marn de salive
US7964408B1 (en) 2004-05-13 2011-06-21 University Of South Florida Lysophospholipids as biomarkers of ovarian cancer
EP1761648A1 (fr) * 2004-06-18 2007-03-14 Roche Diagnostics GmbH Utilisation de la proteine pdx1 comme marqueur pour le cancer du sein
AU2005267148A1 (en) * 2004-07-01 2006-02-02 University Of Southern California Genetic markers for predicting disease and treatment outcome
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
EP1802764A4 (fr) * 2004-09-17 2010-02-03 Univ Johns Hopkins Marqueurs biologiques destines au cancer du sein
US7504225B2 (en) * 2005-05-12 2009-03-17 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
WO2007033367A2 (fr) * 2005-09-14 2007-03-22 The Regents Of The University Of California Proteine et arn salivaires permettant la detection du cancer du sein
KR100828539B1 (ko) * 2005-09-20 2008-05-13 후지제롯쿠스 가부시끼가이샤 이차원 코드의 검출 방법, 검출 장치, 및 검출 프로그램을기억한 기억 매체
WO2007048107A2 (fr) * 2005-10-19 2007-04-26 Heska Corporation Profilage protéomique de tumeurs de cellule souche et procédés associés, protéines et molécules d’acide nucléique
EP1946118A4 (fr) * 2005-11-10 2009-01-21 Aurelium Biopharma Inc Diagnostic tissulaire du cancer du sein
EP2010922B1 (fr) 2006-04-03 2012-06-27 Oratel Diagnostics, LLC Procédés pour criblage d'endométriose
ATE537450T1 (de) * 2006-06-30 2011-12-15 Schering Corp Igfbp2-biomarker
WO2008088343A1 (fr) * 2007-01-19 2008-07-24 Biophysical Corporation Procedes de fourniture de service d'evaluation d'etat de sante individualise
WO2008124525A1 (fr) * 2007-04-03 2008-10-16 Vanderbilt University Nanoparticules avec des éléments de reconnaissance moléculaires
WO2009039023A2 (fr) 2007-09-18 2009-03-26 Board Of Regents Of The University Of Texas System Détection dans la salive, de protéines modulées produites suite à un carcinome canalaire in situ du sein
WO2011133770A2 (fr) * 2010-04-21 2011-10-27 Board Of Regents Of The University Of Texas System Marqueurs de protéines salivaires permettant de détecter le cancer du sein
WO2012024095A2 (fr) 2010-08-20 2012-02-23 Oratel Diagnostics, Llc Surveillance de cycle œstral par réponse colorée
EP2683419B1 (fr) 2011-03-11 2018-05-09 Vib Vzw Molécules et procédés d'inhibition et de détection de protéines
WO2013009813A1 (fr) 2011-07-11 2013-01-17 Oratel Diagnostics, Llc Méthodes et kit de diagnostic de l'endométriose
PE20141565A1 (es) 2011-11-15 2014-10-25 Univ Miami Metodos para detectar papilomavirus humano y proporcionar pronostico para carcinoma de celulas escamosas de cabeza y cuello
CN104142397A (zh) * 2014-08-06 2014-11-12 厦门大学 胸腺素alpha原在制备乳腺癌诊断标记物中的应用
JP7344631B2 (ja) * 2015-02-09 2023-09-14 アボゲン， インコーポレイティド サンプル収集関連応用、分析および診断のためのデバイス、溶液および方法
JP2017211886A (ja) * 2016-05-26 2017-11-30 株式会社ブラケアジェネティクス 女性の健康増進に有用なカスタマイズ情報の提供システム
JP2020511933A (ja) * 2016-11-22 2020-04-23 プライム ゲノミクス，インク． 癌検出のための方法
SG11201909949XA (en) 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
KR102018171B1 (ko) * 2017-10-16 2019-09-04 헨리기술 주식회사 타액을 이용한 유방암 감지 키트 및 이를 이용한 유방암 감지 방법
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US11078256B2 (en) 2018-06-26 2021-08-03 The Board Of Regents Of The University Of Texas System Methods and compositions for inhibiting cancer cell growth
WO2020236875A1 (fr) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Immunotolérance ciblée madcam
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US5512657A (en) 1988-12-12 1996-04-30 Bainbridge Sciences, Inc. Detection of complexes which include basement membrane components as diagnostic of cancer and other diseases
US5527676A (en) * 1989-03-29 1996-06-18 The Johns Hopkins University Detection of loss of the wild-type P53 gene and kits therefor
JP3859695B2 (ja) * 1989-08-04 2006-12-20 バーレックス ラボラトリーズ インコーポレイテッド Ｃ―ｅｒｂＢ―２外部ドメイン：ＧＰ７５
EP1736152A3 (fr) 1993-10-29 2009-10-07 The Trustees Of Boston University Compositions physiologiquement stables d'acide butyrique, de sels et de dérivés d'acide butyrique pour traiter les plaies
AU1837495A (en) * 1994-10-13 1996-05-06 Horus Therapeutics, Inc. Computer assisted methods for diagnosing diseases
US5840889A (en) 1996-04-19 1998-11-24 The Board Of Regents Of The University Of Nebraska Synthesis of estrogen-purine base and estrogen-mercapturate adducts and development of fluorescent probes and monoclonal antibodies to assay those adducts
US5858683A (en) 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
US7393823B1 (en) * 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US6294349B1 (en) * 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100343280C (zh) * 2004-02-04 2007-10-17 香港中文大学 癌症病程及治疗反应的标志物cudr
CN101234026B (zh) * 2008-03-07 2010-04-14 李立 一种乳腺病变定量化影像评价系统
CN111247432A (zh) * 2017-10-16 2020-06-05 亨利技术有限公司 使用唾液的乳腺癌检测试剂盒及乳腺癌检测方法以及使用唾液的可孕期检测试剂盒及可孕期检测方法
CN110297082A (zh) * 2019-06-12 2019-10-01 杭州启创生物技术有限公司 唾液尿酸等标志物特异性检测和诊断痛风的方法

Also Published As

Publication number Publication date
US20020015964A1 (en) 2002-02-07
US6670141B2 (en) 2003-12-30
EP1161680A4 (fr) 2002-04-17
US6294349B1 (en) 2001-09-25
CA2363566A1 (fr) 2000-09-08
WO2000052463A1 (fr) 2000-09-08
US6972180B1 (en) 2005-12-06
EP1161680A1 (fr) 2001-12-12
NO20014223D0 (no) 2001-08-31
HK1044816A1 (zh) 2002-11-01
MXPA01008794A (es) 2003-07-28
WO2000052463A9 (fr) 2002-04-11
AU3613400A (en) 2000-09-21
NO20014223L (no) 2001-10-23
BR0008709A (pt) 2001-12-18
JP2002538462A (ja) 2002-11-12

Similar Documents

Publication Publication Date Title
CN1349611A (zh) 诊断和监测恶性乳腺癌的方法
Esteva et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
RU2005103824A (ru) Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2
JP2006508336A5 (fr)
Purdie et al. Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study
JP2012103264A (ja) 癌診断用抗体
Oyama et al. Evaluation of serum HER2-ECD levels in patients with gastric cancer
JP2008545499A (ja) 生体内発現プロファイリング
Nyström et al. Improved tumour marker sensitivity in detecting colorectal liver metastases by combined type IV collagen and CEA measurement
CN112345755A (zh) 乳腺癌的生物标志物及其应用
CN109270269A (zh) 一种用于早期乳腺癌多联检测的荧光免疫层析检测卡、试剂盒
Wang et al. Quantitative detection of the tumor-associated antigen large external antigen in colorectal cancer tissues and cells using quantum dot probe
JP6626037B2 (ja) 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法
Sangrajrang et al. Serum p53 antibodies in correlation to other biological parameters of breast cancer
Fernandez-Pol Increased serum level of RPMPS-1/S27 protein in patients with various types of cancer is useful for the early detection, prevention and therapy
JP2015525358A (ja) 組織切片中の単一細胞におけるマーカー定量
CN107266567A (zh) Lcrmp4单克隆抗体及其制备方法与应用
CN106990080A (zh) 一种基于液体活检的非小细胞肺癌检测的试剂盒
Carney The emerging role of monitoring serum HER-2/neu oncoprotein levels in women with metastatic breast cancer
Ma et al. Establishing a detection method for CCNY: a potentially significant clinical investigative marker in NSCLC patients
Mokhtari et al. Utility of Serum HER-2/neu in prediction of tissue HER-2/neu status of primary breast cancer
Rasul et al. Study of HER2/neu status in Qatari women with breast carcinoma
JP3779294B2 (ja) 癌およびリウマチの診断剤、並びに検査・診断方法
Colnaghi The simultaneous expression of c-erbB-2 oncoprotein and laminin receptor on primary breast tumors has a predicting potential analogous to that of the lymph node status
Kulkarni et al. HER2-positive early breast cancer and trastuzumab: a surgeon’s perspective

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication